... RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected]. Abstract Aims The REDUCE-AMI trial showed that beta-blockers in patients with preserved left ventricular ejection fraction (LVEF) after acute myocardial...

... The 2023 ESC guidelines for acute coronary syndrome note that contemporary data are heterogenous regarding beta-blocker (BB) use post-myocardial infarction (MI) in patients without reduced ejection fraction (EF) or heart failure (HF). We aimed to address the heterogeneity in contemporary data around BB...

... through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected]. Abstract Aims In patients with advanced heart failure requiring dobutamine infusion, it is usually recommended to initiate beta-blockers after...

.../501100006095 Vestre Viken Hospital Trust Atrial fibrillation Rate control Beta-blockers Calcium channel blockers Natriuretic peptides Rhythm-related symptoms Graphical Abstract Graphical Abstract Figure developed by the authors with venngage.com with licence to use, reproduce and distribute...

... University Press, Standard Journals Publication Model ( https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model ) Abstract Background and aims The evidence for beta-blocker therapy after myocardial infarction (MI) is randomized trials conducted more than 30...

... in myocardial stunning with left ventricular wall motion abnormalities typical of TTS. This pathophysiological framework suggests a potential role for long-term treatment with beta-blockers (BBs) and renin–angiotensin–aldosterone system inhibitors (RAASi), albeit in the absence of evidence from randomized...

... summary of the methods and main findings illustrating the difference in outcomes after first-time myocardial infarction between patients discontinuing and continuing beta-blockers in each landmark year. MI, myocardial infarction; BB, beta-blocker; PCI, percutaneous coronary intervention; CAG, coronary...

... at the National Amyloidosis Centre between 2000 and 2022 identified 2371 patients with ATTR-CA. Prescription of heart failure medications was greater among patients with a more severe cardiac phenotype, comprising beta-blockers in 55.4%, angiotensin-converting enzyme inhibitors (ACEis)/angiotensin II receptor...

... Regulation regulations and appropriate ethics committees. Of 12   421 patients with HFmrEF (EF 40–49%, median HF duration 2.5 years, interquartile range 0.9–6.4), 10   419 (84%) received RASI/ARNI, of whom 151 (1.4%) received ARNI, and 10   941 (88%) received beta-blockers (Graphical Abstract). Patients...

...Markus Meyer; Daniel Lustgarten Figure 1 Illustration of the haemodynamic effects of heart rate reductions with beta-blockers on left atrial and ventricular volumes and pressure. BNP, B-type natriuretic peptide; HFpEF, heart failure with a preserved ejection fraction; LA, left atrial; LVEDP, left...

... Biomarkers Pre-operative coronary artery revascularization Peri-operative cardiac management Anti-thrombotic therapy Peri-operative beta-blockers Pre-operative treatment of valvular disease Peri-operative treatment of arrhythmias Post-operative cardiac surveillance Peri-operative myocardial injury...

... or discontinuing use altogether. Based on several clinical studies, this review discusses the efficacy, safety and role of intravenous landiolol in acute HR control in patients with atrial tachyarrhythmias and ADHF. Atrial fibrillation Beta blockers Landiolol Heart failure Rate control Atrial tachyarrhythmias...

... native artery disease and maintained graft patency. ^2–5 Secondary prevention medication, with platelet inhibitors, beta blockers, renin–angiotensin system (RAS) inhibitors, and lipid-lowering drugs, is recommended in current guidelines to patients with previous myocardial infarction (MI...

... evaluated the effects of beta-blockers (BBs), angiotensin receptor blockers (ARBs), and angiotensin-converting enzyme inhibitors (ACEI) on trastuzumab- and anthracycline-associated cardiotoxicity. We report a meta-analysis of these RCTs in patients with breast cancer. Methods and results The primary...

... to compare the efficacies among Renin-Angiotensin-Aldosterone inhibitors (RAASi) and beta-blockers (BB) to lower trastuzumab-associated cardiotoxicity risks. Method and Results Comprehensive literature searching was conducted through online databases then followed the PRISMA guideline. Studies included...

... the chance for cavitation. Both decreased the possibility of ACS. Funding Acknowledgement Type of funding sources: None. Artery with centerline Measuring the diameter of the artery by Beta-Blockers 3004 Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Beta-Blockers Protective...

..., Standard Journals Publication Model ( https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model ) Abstract Background Beta Blockers (BB) have been the standard of care after acute myocardial infarction (AMI) since the 1960's. There is good evidence of clinical...

...: Private company. Main funding source(s): The study was supported by a research grant from Merck. Beta-Blockers Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Beta-Blockers 3005 Ef cacy & tolerability of bisoprolol in comparison to metoprolol in Indian patients with stage-1 hypertension...

...Thomas Rolland; Nicolas Badenco; Carole Maupain; Guillaume Duthoit; Xavier Waintraub; Mikael Laredo; Caroline Himbert; Robert Frank; Francoise Hidden-Lucet; Estelle Gandjbakhch Cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy/dysplasia Antiarrhythmic drugs Flecainide Beta-blockers...

..., and the impact of beta-blockers (BBs) on outcomes in patients with COPD. Methods and results A systematic review and meta-analysis was conducted according to international guidelines. All studies reporting the prevalence of COPD in AF patients were included. Data on comorbidities, BBs and oral anticoagulant...